TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome
Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment modality available for patients with myelodysplastic syndrome (MDS). Clinical outcomes after HCT are highly variable and the selection of patients who will benefit from allogeneic HCT is essential. Allogeneic HCT is primarily recommended for higher-risk MDS patients based on findings from previous studies using Markov models that suggested the importance of appropriate timing for HCT [1]. These statistical models showed that a decision to delay HCT would maximize survival in patients with low or intermediate-1 scores in the International Prognostic Scoring System (IPSS), whereas immediate HCT at the time of diagnosis would lead to longer survival in IPSS intermediate-2 or high risk patients [2,3].
Source: Leukemia Research - Category: Hematology Authors: Yoo-Jin Kim, Seung-Hyun Jung, Eun-Hye Hur, Eun-Ji Choi, Kyoo-Hyung Lee, Seon-Hee Yim, Hye-Jung Kim, Yong-Rim Kwon, Young-Woo Jeon, Sug Hyung Lee, Yeun-Jun Chung, Je-Hwan Lee Tags: Research paper Source Type: research